Prime Medicine Capital Raise of $144M
Prime Medicine, Inc. entered into an underwriting agreement for a public offering of 35,714,286 shares of common stock at $3.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 5,357,142 shares, bringing the total potential gross proceeds to approximately $143.75 million. Proceeds will be used to advance the company's Wilson disease and alpha-1 antitrypsin deficiency programs and for general corporate purposes.
- Value
- $144M
- Counterparty
- Jefferies LLC